快速訂購

PD1/PDCD1/CD279 Immune Checkpoint Inhibitors

PD1/PDCD1/CD279 immune checkpoint inhibitors are drugs, most of which are antibodies, targeting PD1/PDCD1/CD279. These PD1/PDCD1/CD279 immune checkpoint inhibitors are applied to treat cancer. Many PD1/PDCD1/CD279 immune checkpoint inhibitors have been developed or under research. These PD1/PDCD1/CD279 immune checkpoint inhibitors include Nivolumab, PembrolizumabIn, Pidilizumab, AMP-224 and so on. They are tested in multiple cancers: Melanoma, Non-small cell lung cancer, Small cell lung cancer……

PD1/PDCD1/CD279 Immune Checkpoint Inhibitors: Developments

Disease PD1/PDCD1/CD279 immune checkpoint inhibitors' research development
Melanoma Nivolumab —— is tested as a PD1/PDCD1/CD279 immune checkpoint inhibitors antibody in a phase III study in patients with metastatic melanoma (Larkin et al. 2015).
Pembrolizumab —— in a randomized, controlled, phase 3 study, 834 patients with advanced melanoma are assigned to receive the PD1/PDCD1/CD279 immune checkpoint inhibitors drug, pembrolizumab (Robert et al. 2015).
Pidilizumab—— a Phase 2 multicenter, randomized, open-label, study is initiated to evaluate the safety and efficacy of pidilizumab, as one of the PD1/PDCD1/CD279 Immune Checkpoint Inhibitors, in patients with metastatic melanoma (Atkins et al. 2014)
Non-small cell lung cancer nivolumab —— a fully human PD1/PDCD1/CD279 immune checkpoint inhibitors antibody is tested in a randomized, global phase III study in patients with NSCLC (Paz-Ares et al. 2015).
Pembrolizumab (MK-3475)—— This Phase I study is conducted to evaluate the safety, tolerability, and clinical activity of MK-3475, a selective anti-PD1/PDCD1/CD279 antibody, and a member of immune checkpoint inhibitors (Garon et al. 2014).
AMP-224—— a special PD1/PDCD1/CD279 immune checkpoint inhibitor drug, which is a B7-DC-Fc fusion protein and can block the PD1/PDCD1/CD279 receptor competitively(Mkrtichyan M et al. 2012).
Small cell lung cancer Two fully human PD1/PDCD1/CD279 immune checkpoint inhibitors monoclonal antibodies have been tested in patients with small cell lung cancer: nivolumab (Antonia et al. 2015), and pembrolizumab (Ott et al. 2015).
Hepatocellular carcinoma (HCC) There is only one PD1/PDCD1/CD279 immune checkpoint inhibitors drug, pembolizumab, have been tested in patients with hepatocellular carcinoma (HCC; El-Khoueiry et al. 2015).
Head and neck cancer To date, one PD1/PDCD1/CD279 immune checkpoint inhibitors drug, pembolizumab, has been tested in patients with recurrent/metastatic head and neck cancer (Seiwert et al. 2015).
Nivolumab (Opdivo) is a PD1/PDCD1/CD279 immune checkpoint inhibitors drug. Based on promising results from a phase I clinical trial, the drug's manufacturer, Bristol-Myers Squibb, has launched phase III trials of the agent in several cancers, including head and neck cancer (NCT02105636).
Urothelial cancer In a phase I trial cohort for recurrent, metastatic, or persistent urothelial cancer of the bladder, renal pelvis, ureter, or urethra, a PD1/PDCD1/CD279 immune checkpoint inhibitors drug, pembrolizumab demonstrated preliminary efficacy and safety in this patient population (Plimack et al. 2015).
Brain cancer Nivolumab —— A phase III trial test Opdivo® (nivolumab) —a PD1/PDCD1/CD279 immune checkpoint inhibitors drug in patients with recurrent glioblastoma (NCT02017717).
Pembrolizumab —— A phase II trial tested Keytruda® (pembrolizumab), a PD1/PDCD1/CD279 immune checkpoint inhibitor, with or without Avastin® (bevacizumab), in patients with recurrent glioblastoma multiforme (NCT02337491).
Colorectal cancer Pembrolizumab (Keytruda®, MK-3475) —— a phase II study of pembrolizumab (Keytruda®, MK-3475), a PD1/PDCD1/CD279 immune checkpoint inhibitors drug made by Merck, was conducted for patients with microsatellite unstable (MSI) tumors, including colorectal cancer (NCT01876511).
Nivolumab ——a phase I/II trial of nivolumab (Opdivo®), PD1/PDCD1/CD279 immune checkpoint inhibitors drug, +/- ipilimumab (Yervoy®), an anti-CTLA-4 antibody, in patients with recurrent and metastatic colon cancer (NCT02060188).
Esophageal cancer Nivolumab (ONO-4538) is a PD1/PDCD1/CD279 immune checkpoint inhibitors drug being developed by ONO/Bristol-Myers Squibb that is in a phase II trial for patients with advanced esophageal cancers (JapicCTI-142422).
Kidney cancer Pembrolizumab (Keytruda, MK-3475) —— a phase III study of pembrolizumab, a PD1/PDCD1/CD279 immune checkpoint inhibitors drug being developed by Merck, was conducted in patients with advanced urothelial cancer, including the renal pelvis (NCT02256436).
Nivolumab (Opdivo) —— a phase III study of nivolumab (Opdivo), a PD1/PDCD1/CD279 immune checkpoint inhibitors drug, with ipilimumab (Yervoy), a CTLA-4 immune checkpoint inhibitor, both made by Bristol-Myers Squibb, versus sunitinib (Sutent), for patients with previously untreated advanced or metastatic renal cell carcinoma (NCT02231749).
Leukemia Nivolumab (Opdivo®, a PD1/PDCD1/CD279 immune checkpoint inhibitors drug ) —— There is a phase II study of nivolumab for patients with (acute myeloid) AML to eliminate residual disease and maintain remission after chemotherapy (NCT02275533)
Pembrolizumab (Keytruda®, a PD1/PDCD1/CD279 immune checkpoint inhibitors drug ) —— A phase II study of pembrolizumab was conducted in patients with relapsed or refractory chronic lymphocytic (CLL) (NCT02332980).
Lymphoma Nivolumab —— A phase II study of nivolumab, a PD1/PDCD1/CD279 immune checkpoint inhibitors drug is conducted for patients with relapsed or refractory follicular lymphoma (NCT02038946).
Pembrolizumab —— There was a phase Ib trial of the PD1/PDCD1/CD279 immune checkpoint inhibitor, pembrolizumab in patients with hematologic malignancies including Hodgkin lymphoma and non-Hodgkin lymphoma (NCT01953692)
Multiple myeloma Pembrolizumab —— Two phase I trials of pembrolizumab (MK-3475), a PD1/PDCD1/CD279 immune checkpoint inhibitors drug being developed by Merck, are enrolling patients with multiple myeloma (NCT02036502) and with blood cancers, including multiple myeloma (NCT01953692).
Nivolumab —— a PD1/PDCD1/CD279 immune checkpoint inhibitors drug, and ipilimumab, a CTLA-4 immune checkpoint inhibitor, are in a phase I trial testing it in blood cancers, including multiple myeloma (NCT01592370).
Pidilizumab —— A phase II clinical trial is testing pidilizumab (CT-011), a PD1/PDCD1/CD279 immune checkpoint inhibitors drug, plus a dendritic cell fusion vaccine in multiple myeloma (NCT01067287).

PD1/PDCD1/CD279 Immune Checkpoint Inhibitors: Relatives

PD-L1/B7-H1/CD274 immune checkpoint inhibitors What is PD1 / PDCD1 / CD279 immune checkpoint
CTLA-4/CD152 immune checkpoint inhibitors PD1 / PDCD1 / CD279 immune checkpoint pathway
B7-H3/CD276 immune checkpoint inhibitors PD1 / PDCD1 / CD279 immune checkpoint antibodies
Indoleamine 2,3‑dioxygenase/IDO immune checkpoint inhibitors PD1/PDCD1/CD279 immune checkpoint inhibitors
PD1/PDCD1/CD279 immune checkpoint inhibitors PD1 / PDCD1 / CD279 immune checkpoint research
LAG3 / CD223 immune checkpoint inhibitors Immune checkpoint blockade: PD1 / PDCD1 / CD279 blocking antibodies
請注意:所有產品都是“僅用於科研,而不能用於診斷或治療用途”